Brivaracetam in epilepsy: Added benefit not proven

May 27, 2016

Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adolescents from the age of 16 years and adults with epileptic seizures. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug offers an added benefit for patients in comparison with the appropriate comparator therapy.

The drug manufacturer presented no data from a study of direct comparison, and the indirect comparisons conducted in its dossier were unsuitable for the derivation of an added benefit for several reasons. IQWiG therefore sees no hint of an added benefit of brivaracetam in comparison with the appropriate comparator therapy.

Ten drugs suitable as individual antiepileptic add-on therapy

The appropriate comparator therapy specified by the Federal Joint Committee (G-BA) was an individual antiepileptic add-on therapy, which can consist of one of ten drugs named by the G-BA depending on subindication, resistances or intolerances.

In its dossier, the manufacturer limited itself to the two antiepileptic drugs lacosamide and eslicarbazepine without showing that these constituted the add-on therapy customized for the individual patient in each case.

Indirect comparisons not evaluable

Irrespective of the question whether or not lacosamide and eslicarbazepine were the therapy customized for the individual patient in the studies presented by the manufacturer, IQWiG investigated the data presented in the dossier for their suitability for a benefit assessment. It concluded that the indirect comparisons conducted by the company on the basis of 15 studies on the three drugs were not evaluable.

In some cases, the studies themselves were irrelevant for the comparisons, for example because brivaracetam was not titrated for the individual patient as recommended in the Summary of Product Characteristics, or because the studies were too short. In some cases, the studies compared were not sufficiently similar. Moreover, the comparisons were incomplete because the manufacturer did not present analyses on patient-relevant outcomes.

Since no suitable data were available, an added benefit of brivaracetam is not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the Website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealth.org).

If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.
-end-


Institute for Quality and Efficiency in Health Care

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.